CURRICULUM VITAE ROHIT LOOMBA, MD, MHScjacobsschool.ucsd.edu/uploads/agile_faculty/cv/loomba_rohit.pdf · 2014 Asia Pacific Association for the Study of Liver Diseases Annual Meeting,

CURRICULUM VITAE

ROHIT LOOMBA, MD, MHSc

CURRENT POSITION Professor of Medicine (with tenure) Division of Gastroenterology Department of Medicine

Director, NAFLD Research Center Director, Liver Epidemiology Training Program

Adjunct Professor Division of Epidemiology Department of Family Medicine and Public Health T. Franklin Williams Scholar

CURRENT ADDRESS University of California, San Diego

Division of Gastroenterology 9500 Gilman Drive (BRF-II/4A-18) La Jolla, CA 92093-0063 Phone: 858-534-2624 Home: 858-509-7567 E-mail: [email protected]

Website: Fattyliver.ucsd.edu DATE OF BIRTH October 17, 1975 CITIZENSHIP United States EMPLOYMENT 2009-2011 Assistant Professor of Clinical Medicine, Step II Division of Gastroenterology Assistant Adjunct Professor, Step II Division of Epidemiology University of California, San Diego, CA 2011- 2013 Assistant Professor of Clinical Medicine, Step III Division of Gastroenterology Assistant Adjunct Professor, Step III Division of Epidemiology University of California, San Diego, CA 2013- 2015 Associate Professor of Clinical Medicine, Step II Division of Gastroenterology Associate Adjunct Professor, Step II Division of Epidemiology University of California, San Diego, CA 2013-pres Associate Director of Clinical Research, Division of Gastroenterology 2013-pres Co-Director, Translational Core Division of Gastroenterology 2015-2015 Professor of Clinical Medicine, Step 1 Division of Gastroenterology 2015-pres Professor of Medicine in Ladder Rank (with tenure), Step 1 Division of Gastroenterology

Curriculum Vitae of Rohit Loomba, MD, MHSc

Page 2 of 27

2015-pres Adjunct Professor Division of Epidemiology TRAINING 07/07 - 06/09 Gastroenterology Fellowship University of California, San Diego, CA 06/04 - 06/07 Hepatology Fellowship NIH/NIDDK, Bethesda, MD 11/03 – 06/04 Chief Resident, Internal Medicine St. Luke’s Hospital, St. Louis, MO 11/00 – 11/03 Internal Medicine Residency St. Luke’s Hospital, St. Louis, MO EDUCATION 08/05 – 05/07 Masters of Health Science in Clinical

Research (NIH-Duke University Combined Program)

Duke University School of Medicine, Durham, NC

08/93 – 03/99 M.B.B.S. The Armed Forces Medical College, India MEDICAL LICENSURE

Medical licensure in the state of California and Maryland. Permanent license to practice medicine in India

EXAMINATION

Board certified in Internal Medicine 2004 Board certified in Gastroenterology 2009 USMLE Step 1, 2, 3 and CSA passed

AWARDS AND ACHIEVEMENTS

2002 AGA/Wyeth Resident Reporter Award 2002 American Liver Foundation/American Association of the Study of Liver Diseases

Resident Scholar Award 2008 Salix Travel Award for clinical excellence: AASLD 2008 Fellows Travel Award for Outstanding Abstract: GI/Hepatology Mayo Clinic 2008 First prize, Fellows abstract competition, San Diego Gastroenterology Society 2009 First prize, Fellows abstract competition, San Diego Gastroenterology Society 2009-2012 American Gastroenterological Association Foundation – Sucampo – ASP Designated

Research Scholar Award in Geriatric Gastroenterology 2009 T Franklin Williams Scholarship Award 2012 Health Heros Award by the combined health agencies supported by the American Liver

Foundation 2013 TFWS Alumni Executive Leadership Award- 2013 AAIM Executive Leadership

Program 2015 ALF-Pacific Chapter Gala Honoree 2015

PATENTS/INVENTIONS 2014 International Patent Application Submitted US Patent and Trademark Office : Title of the

Invention: Differential Diagnosis of Liver Disease (Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis)


Page 3 of 27

2015 Provisional Patent Application Submitted US Patent and Trademark Office: Title of the Invention: Differential Diagnosis of Liver Disease (Quantitative Determination of Esterified Eicosanoids)

PROFESSIONAL SOCIETIES

American Association for the Study of Liver Diseases. American Gastroenterology Association. Gastroenterology Research Group. American College of Gastroenterology

REVIEWER FOR JOURNALS 2007-pres The Annals of Internal Medicine 2008-pres Alimentary Pharmacology and Therapeutics 2008-pres Clinical Endocrinology 2008-pres Clinical Gastroenterology and Hepatology 2008 Chemotherapy 2008 Expert opinion in drug therapy 2009-pres Gastroenterology 2009-pres The American Journal of Gastroenterology 2009-pres Hepatology 2009-pres Liver Transplantation 2009 Journal of Infection 2012-pres Journal of Clinical and Experimental Hepatology 2012-pres Diabetes Care 2012-pres Digestive and Liver Disease 2012-pres Digestive Disease Sciences 2012-pres Journal of Hepatology 2012-pres Liver International 2012-pres British Medical Journal 2014-pres Journal of American Medical Association 2014-pres The New England Journal of Medicine 2015-pres Science 2015-pres Nature ASSOCIATE EDITOR FOR JOURNAL 2014-pres Alimentary Pharmacology and Therapeutics EDITORIAL BOARD FOR JOURNALS 2011-pres Alimentary Pharmacology and Therapeutics 2011-pres Liver International 2012-pres Journal of Clinical and Experimental Hepatology 2013-pres World Journal of Gastroenterology 2014-pres BMJ Gastroenterology 2014-pres Gastroenterology 2015-pres GUT 2015-pres Journal of Hepatology ABSTRACT REVIEWER FOR ACADEMIC SOCIETIES

DDW 2009; section: Influence of environment and obesity on GI cancers


Page 4 of 27

DDW2010; section: Influence of environment and obesity on GI cancers DDW2011; section: Influence of environment and obesity on GI cancers DDW2012; section: Influence of environment and obesity on GI cancers DDW2011; section: Viral hepatitis: epidemiology AASLD 2010; section: Viral hepatitis: epidemiology AASLD 2011; section: Viral hepatitis: epidemiology AASLD 2012; section: Viral hepatitis: epidemiology DDW2013; section: Influence of environment and obesity on GI cancers AASLD 2013; section: Viral hepatitis: epidemiology DDW2014; section: Influence of environment and obesity on GI cancers AASLD 2014; section: Imaging in liver disease DDW 2015; section: Influence of environment and obesity on GI cancers AASLD 2015; section, Imaging in liver disease DDW 2016; Chair; section: Influence of environment and obesity on GI cancers

PROFESSIONAL SOCIETY COMMITTEE MEMBERSHIP AND SERVICE

2008-2010 Member- AASLD Training and Clinical Policy Committee 2008-pres Member- AASLD Steatosis and steatohepatitis special interest group 2009-2011 Member-AASLD Publications Committee 2009-2012 Member- AGA- International Committee 2009 Co-Director: Career Development Workshop: AASLD 2010 Director: Career Development Workshop: AASLD 2011-2015 Elected to the National Board of Directors, The American Liver Foundation 2011-2013 Member-AASLD Annual Meeting Education Committee 2013-2016 Member- AASLD Research Awards Committee 2013-2016 Member- AASLD Program Evaluation Committee 2014-2016 Member- AGA-Research Award Panel 2015-2017 Elected member of the Steering Committee: AASLD Steatosis and Steatohepatitis special

interest group 2014-2016 Elected Chair-ALF Research Awards Committee

INVITED PRESENTATIONS AT NATIONAL SOCIETY & INTERNATIONAL MEETINGS

2009 AASLD: Effective Menteeship: Invited talk 2010 EPD (Spanish GI Society) and AGA joint symposium- Santiago de Compestela, Spain (Invited) 2010 AASLD: Junior Faculty Perspective in Academic Advancement (Invited) 2010 AASLD Postgraduate Course: Faculty: Meet the Professor Luncheon 2011 NCCAM/NIH Invited presentation in a round table meeting of experts “Current Research and

Future Directions for Vitamin E Treatment of Nonalcoholic Fatty Liver Disease,” May 2, 2011. 2011 AASLD Postgraduate Course: Faculty: Meet the Professor Luncheon 2011 AGA Digestive Disease Week: Mentor-Mentee Forum: Clinical Research Perspective (Invited) 2011 “Prophylaxis and Therapy of HBV and Viral Hepatitis in Immunocompromised Patients" –

Torino, Sept. 29-30, 2011, sponsored by the Italian Association for the Study of Liver Diseases 2011 EUGW: Invited talk: “Synergistic Effect of Alcoholc and Obesity on Liver Disease; Joint

Symposium of AGA and ASGNME (joint european GI societies), Stockholm, Sweden. 2012 INASL, Guwahati, India: “Changing the management paradigm in NASH” 2013 INASL, Hyderabad, India. “Management of NAFLD” 2013 DDW, Orlando: AASLD Combined Clinical Symposium. “How to predict treatment response in

NASH?” 2013 DDW, Orlando: AASLD and AGA Clinical Symposium. “Non-invasive biomarkers of NAFLD” 2013 FDA/AASLD Workshop: Trial Designs and Endpoints for Liver Disease Secondary to

Nonalcoholic Fatty Liver Disease (NAFLD); invited speaker, “What are the Key Clinical


Page 5 of 27

Questions that Require Development of Diagnostic Tools?”; September 5-6, 2013, Silver Spring, MD

2013 AASLD: SIG Program: Selected Controversies in Adult and Pediatric NAFLD and NASH; invited speaker. "First Line Therapy or Waiting for Something Better?"

2014 Alpha-1 foundation scientific meeting: “Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases”. Invited speaker, “Monitoring liver disease”. February 3-4, Bethesda, MD

2014 Asia Pacific Association for the Study of Liver Diseases Annual Meeting, Brisbane, Australia: Invited Speaker, “Novel therapies for hepatitis B”. March, 2014

2014 Digestive Disease Week, Chicago, IL: Chair and Speaker “Similarities and differences in ASH and NASH”. May, 2014

2014 LIPIDMAPS Annul Meeting, La Jolla, CA; Invited speaker: “Key clinical issues in the management of nonalcoholic fatty liver disease”. May, 2014

2014 9th Annual Advanced Liver Disease and Liver Transplantation, University of Michigan, Ann Arbor, MI: “Magnetic resonance Imaging and transient elastography in the assessment of liver disease”. May, 2014

2014 19th Annual Korean Association for the Study of Liver Diseases meetings, Jeju, Korea: “Turning points in CHB patient care: how far can we go?” June, 2014

2014 74th Annual American Diabetes Association meetings, San Francisco, CA: “The Diagnostic Challenge of Non-Alcoholic Fatty Liver Disease--Role of Plasma Biomarkers, Imaging, and Liver Biopsy”. June, 2014

2015 American Gastroenterology Association Clinical Congress, Miami, FL. Invited Lecture, “I just diagnosed NAFLD what do I do now?”. January 2015

2015 30th Annual Liver Disease Update. Scripps Clinic, La Jolla, CA. Invited Lecture, “Emerging therapies for NASH”. March 2015

2015 AASLD Mid-Year Annual Clinical Congress, Chicago, IL. Invited lecture. “Emerging and standard therapies for alcoholic hepatitis and NASH”. June 2015

VISITING PROFESSORSHIPS

2011: AIIMS, New Delhi, India: Invited talk: “Management of NAFLD” 2011 PGIMER, Chandigarh, India: Invited talk: “Management of NAFLD” 2012 INASL, Guwahati, India: “Changing the management paradigm in NASH” 2012: University of California, Irvine: Visiting Professor “Epidemiology of NAFLD” 2013: University of Alabama, Birmingham: Visiting Professor “Changing the management paradigm in NAFLD” 2013: INASL, Hyderabad, India. “Management of NAFLD” 2013: Emory University, Atlanta, GA: Visiting Professor, GI grand rounds "Key clinical questions in the management of nonalcoholic fatty liver disease," October 7th 2013: Emory University, Atlanta, GA: Visiting Professor, Medicine grand rounds "Cardiometabolic risk factors and treatment of nonalcoholic steatohepatitis," October 8th 2013: Johns Hopkins University, Baltimore, MD: Visiting Professor, 39th Annual Topics in Gastroenterology and Hepato-Biliary Update. November 6, 2013 2014: Mayo Clinic, Rochester, MN: GI Grand Rounds, “Key clinical issues in the assessment of nonalcoholic fatty liver disease”. January, 2014 2014: University of Michigan, MI: Hepatology Invited Lecture, “Key issues in NASH trials”. May, 2014 2015: Brook Army Medical Center, San Antonio, Gastroenterology Grand Rounds: “Innovations in clinical trial design and novel imaging in NAFLD”. August 2015

NIH COMMITTEE MEMBERSHIP AND SERVICE

2009-2019 NIDDK/NIH Member- Steering Committee, Nonalcoholic Steatohepatitis-Clinical Research Network.


Page 6 of 27

2010-2019 Chair, Standard of Care Committee, Nonalcoholic Steatohepatitis-Clinical Research Network-NIDDK, NIH

2009-2014 Co-Chair, FLINT Trial Protocol Writing Committee Nonalcoholic Steatohepatitis-Clinical Research Network-NIDDK, NIH

2009-2019 Member- Genetics Committee, Nonalcoholic Steatohepatitis-Clinical Research Network-NIDDK, NIH

NIH PANEL MEETINGS/WORKSHOPS/SYMPOSIUM

NCCAM/NIH Invited presentation in a round table meeting of experts “Current research and

future directions for Vitamin E treatment of nonalcoholic fatty liver disease”; in Bethesda, NIH campus: May 2nd, 2011.

Association of Subspecialty Professors, American Geriatric Society, NIA, NHLBI, NIAAA, NCI

and NIDDK joint workshop “Solid organ transplant in elderly”: Role: Member organizing committee and writing committee of the research priorities in the field of solid organ transplant in elderly. January 2012.

FDA/AASLD Workshop: Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease (NAFLD); invited speaker, “What are the Key Clinical Questions that Require Development of Diagnostic Tools?”; September 5-6, 2013, Silver Spring, MD

Alpha-1 Foundation Scientific Meeting: Invited presentation entitled, “Liver Disease Monitoring” in the conference: Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases; organized by the Alpha-1 Foundation, February 4-5, 2014, Bethesda, MD.

Institute of Medicine: meeting for eradication of hepatitis B and C, faculty panel member and invited presentation, “Hepatitis B Reactivation”, November 30-December 1, 2015, Washington D.C

RESEARCH OUTREACH

Founding director and PI of the San Diego Integrated NAFLD Research Consortium (SINC): The San Diego Integrated NAFLD Research Consortium was established by Dr. Loomba (see publication no. 30) in 2011 with the goal of enhancing collaboration between doctors and working groups interested in the research and care of patients with NAFLD. The consortium includes experts of fatty liver disease from 4 major medical centers in the San Diego region including UCSD, Sharp Health Care, Kaiser Permanente, and Balboa Naval Medical Center. Experts from these sites work together on research to advance the understanding of NAFLD.

Research collaboration with Southwestern Oncology Group (SWOG), a National Cancer Institute sponsored research consortia, in understanding the burden of viral hepatitis in cancer patients across SWOG sites in the United States. Overall goal is to better define the epidemiology of viral hepatitis and risk of recurrence of hepatitis B and C and reducing liver related morbidity and mortality in this group of patients. 2010- present

COMMUNITY SERVICE

Pacific Chapter of the American Liver Foundation: Annual Course on Liver Disease, 2011: Invited speaker, “NAFLD”.

Pacific Chapter of the American Liver Foundation: Annual Course on Liver Disease, 2012: Invited speaker, “NAFLD”

Fundraising for pacific Chapter of the American Liver Foundation: Carlsbad Liver Half Marathon Participant, 2012


Page 7 of 27

Fundraising for pacific Chapter of the American Liver Foundation: Carlsbad Liver Half Marathon Participant, 2013

Pacific Chapter of the American Liver Foundation: Annual Course on Liver Disease, 2012: Invited speaker, “Diagnosis and management of NAFLD”

Pacific Chapter of the American Liver Foundation: Annual Course on Liver Disease, 2013: Invited speaker, “Diagnosis and management of NAFLD”

Pacific Chapter of the American Liver Foundation: Annual Course on Liver Disease, 2014: Invited speaker, “State of the art: Management of NAFLD”

UNIVERSITY SERVICE 2008-2009 Member, Research and Career Development Committee, Division of Gastroenterology,

Department of Medicine 2008-present Member, Research and Career Development Committee, Division of Gastroenterology,

Department of Medicine 2009–present Member, Gastroenterology fellowship candidate selection committee, Division of

Gastroenterology, Department of Medicine 2009-present Member, Intern selection committee, Department of Medicine 2009-present Member, Physician-scientist training program candidate selection committee 2009-present Member, Liver transplant selection committee, Center for Hepatobiliary and Abdominal

Transplant, UCSD Medical Center 2009-present Organizer: weekly hepatology journal club: a teaching conference for trainees and faculty

(0.5 CME per meeting) 2009-present Director, NAFLD Clinic, UCSD Medical Center 2009-present Faculty mentor, Cardiovascular Epidemiology T32 Training Program (PI: Michael

Criqui, MD) 2010-2011 Member, Hepatology Faculty Search Committee(s) 2010 Member, Interview panel, GI Division Chief Search Committee 2010 Member, Interview panel, Hepatology Chief Search Committee 2010 Member, Interview panel, GI Division Faculty Search Committee 2010-2011 Member, Hepatology Faculty Search Committee(s) 2010-2011 Medical School Teaching: SOM-208: Organ Physiology GI: Wrote the power-point

slides for the liver part 2010-2011 SP chair for medical students research projects 2010-2011 ISP chair: CREST Program 2010-present Reviewer of grant proposals: Intramural Clinical and Translation Research Institute

(CTRI) pilot and feasibility grants. 2010 GI grand rounds: Epidemiology of NAFLD 2011-present Director, Liver epidemiology training program 2011-present Research Mentor: Gastroenterology T32 training program (PI: Sheila Crowe, MD) 2011 Medical School Teaching: SOM-218: Epidemiology Course: Small group meetings

facilitator 2011 Speaker: Annual CME Meeting on Advances in Internal Medicine 2011 CVD Epidemiology T-32 training program lecture series: Assessing interaction in

epidemiologic studies 2011 Director and organizer: Fifth Annual Gastroenterology Research Retreat 2012 Speaker: Annual CME Meeting on Advances in Internal Medicine 2012 GI grand rounds: Changing the management paradigm in NASH 2013 Speaker: first Annual UCSD Gastroenterology update, Changing the management of

NAFLD, March, 2013 2013-present Associate Director of Clinical Research, Division of Gastroenterology 2013-present Co-Director, Clinical and Translational Core, Division of Gastroenterology 2013-preset Member, Internal advisory committee for gastroenterology T32 training program


Page 8 of 27

2013 GI Grand rounds: Journal club presentation, September 2013 2013 Liver core curriculum teaching, evidence based medicine and evaluation of medical

literature, October, 2013 2013 GI core curriculum teaching, NAFLD, December, 2013 2013 Member, Department of Medicine, Committee for Academic Promotions (DOM CAP) 2014 Member, Search Committee, Director, Liver Transplant Program, and Clinical Service

Chief, Pediatric Gastroenterology, UCSD 2014 Session moderator for the hepatology section; Second Annual UCSD Gastroenterology

and Hepatology update, February, 2014 2015 Session moderator for the hepatology section; Third Annual UCSD Gastroenterology and

Hepatology update, January, 2015 2015 “NASH Clinical Update” Invited presentation ; Third Annual UCSD Gastroenterology

and Hepatology update, February, 2014 2015 “Novel therapies and innovations in clinical trial design in NASH”; Gastroenterology

grand rounds, May 2015 STUDENT/TRAINEE MENTORSHIP

Postdoctoral Students including Fellows, Resident and Interns

1. 2007 Ayana Rowley, PharmD, Post-graduate student year 1 Role: Research Co-Advisor, “Lamivudine in hepatitis B reactivation.”

2. 2008 Andrew Bain, MD, GI Fellow Role: Research Advisor “Role of fluoroquinolones in primary prevention of

spontaneous bacterial peritonitis.” 3. 2008-2009 Lance Stein, MD, GI Fellow

Role: Severed as senior author on review article on treatment of hepatitis B 4. 2009 Erica Boettcher, MD, Medicine Resident

Role: Research Advisor 5. 2009-2010 Benjamin Cohen, MD, GI Fellow NIH T32 Co-Mentor with one publication. Currently a faculty at Mt. Sinai School of Medicine in Gastroenterology. 6. 2009-2010 Mamie Dong, MD, GI Fellow

Role: Research Advisor: Published two first author original research papers with me as senior author and also wrote a review article on NAFLD, finalist in the Annual 2010 San Diego Gastroenterology Society fellows research competition, and poster presentation at Digestive Disease Week 2010.

7. 2009-2010 Jeffrey Lee, MD, Medicine Resident Role: Research Advisor: Presented his research poster at the 2009 Annual American Association for the Study of Liver Disease Meeting and published paper as first author in PLOS One with me as senior author. Currently T32 GI fellow at UCSF.

8. 2010 Benjamin Cohen, MD, GI Fellow Role: ISP Committee Chair for Masters in Clinical Research CREST Currently faculty at Mount Sinai School of Medicine, New York

9. 2011-2012 Thuy-Anh Le, MD, GI Fellow Role: NIH T32 Mentor. Dr. Le has one original research first author paper in Hepatology with me as senior author and another publication in PLOS One. She has a poster presentation of her research at the 2012 Digestive Disease Week Meeting in San Diego. Her work in our lab led to five peer-reviewed publications including one original first author-publication in Hepatology.

10. 2011-2012 Zachary Permutt, MD, Medicine Resident Role: ISP Research Advisor. Dr. Permutt has a poster presentation of his research at the 2012 Digestive Disease Week meeting in San Diego. His work led to one


Page 9 of 27

original research publication as first author in Alimentary Pharmacology and Therapeutics. Currently Chief Resident at UCSD, La Jolla

11. 2011-2012 Brigid Boland, MD, GI Fellow Role: Research Advisor. Dr. Boland presented her research on bilirubin and its association with mortality in the Rancho Bernando Cohort at the 2012 Digestive Disease Week Meeting in San Diego. Her work has been accepted for publication as a first author in Clinical and Experimental Hepatology.

12. 2011-2013 Mazen Noureddin, MD, GI Fellow Role: Research Mentor. Dr. Noureddin was a finalist in the 2012 San Diego Gastroenterology Society Fellows Research Competition and had a poster presentation at the 2011 and 2012 American Association for the Study of Liver Disease Meeting. His work led to two first author original research articles in Hepatology and one review article in Clinical Liver Disease. Currently faculty at University of Southern California, Los Angeles

13. 2012-2013 Iliana Doycheva, MD, Post-Doctoral Research Fellow Role: Research Mentor. Dr. Doycheva presented her research as a poster at 2013 DDW. Her work led to three peer-reviewed publications. Currently a gastroenterology fellow at University of Utah, Salt Lake City

14. 2012-2013 Niraj Patel, MD, Medicine resident Role: Research Mentor. Dr. Patel had poster presentations both at the 2013 DDW and 2013 American Association for the Study of Liver Disease Meeting. His work led to a total of 3 publications with two first author original research articles. Accepted for gastroenterology fellowship, class of 2014 at UCSD.

15. 2013-2014 Michele Pearlman, MD, Medicine resident Role: Research mentor

16. 2013-2015 Janki Patel, MD, Medicine resident Role: Research mentor and ISP chair

17. 2013-2015 Steven Lin, MD, Medicine resident Role: Research mentor and ISP chair

18. 2013-2015 Ahilan Arul, MD, Medicine resident Role: Research mentor and ISP chair

Medical Students

19. 2011-2012 Shanglei Liu, Medical Student (Year 4) Role: ISP Mentor. Data analysis completed and writing the manuscript. Successfully matched to UCSD Surgery Residency Program for 2012-2013.

20. 2014-2015 Jeffrey Cui, Medical Student (Year 3) Role: ISP Mentor: Project title: Non-invasive detection of cirrhosis in NAFLD Role: 1 year research block in my laboratory

Undergraduate Students 21. 2013-2015 Rashmi Jain, Undergraduate Student (Bioengineering: Biotechnology, UCSD) Role: Mentor, Research Advisor.

RESEARCH GRANTS AND AWARDS Agency: NIDDK/NIH Grant No: R01DK106419 Title: QUS technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD Period: 2015-2020 Role: Principal Investigator


Page 10 of 27

Agency: NIH/NIDDK Grant No: U01 DK61734 Title: Clinical Research Network in Nonalcoholic Steatohepatitis Period: 05/01/09 – 04/30/19 Role: Principal Investigator (UCSD Adult Site); (Consortia PI-Joel Lavine, Columbia

University) Agency: NIH/NIDDK Grant No: K23 DK090303 Title: Genetic Epidemiology of NAFLD: A Twin Study Period: 09/15/11 – 06/30/15 Role: Principal Investigator Agency: Daiichi Sankyo Inc Title: Colesevelam versus Placebo for the Treatment of NASH: Randomized Controlled Trial Period: 07/01/09 – 12/31/17 Role: Principal Investigator Type: Investigator-Initiated Study Agency: Merck Inc Title: Ezetimibe versus Placebo for the Treatment of NASH: Randomized Controlled Trial Period: 2013-2016 Role: Principal Investigator Type: Investigator-Initiated Study Agency: Merck Inc Title: Sitagliptin versus Placebo for the Treatment of NAFLD: Randomized Controlled Trial Period: 2013-2018 Role: Principal Investigator Type: Investigator-Initiated Study Agency: Kinemed Inc Title: Kinetic biomarkers of nonalcoholic fatty liver disease and fibrosis Period: 2014-2016 Role: Principal Investigator Type: Investigator-Initiated Study Agency: Promedior Inc Title: Serum Amyloid protein levels as a biomarker for hepatic fibrosis in NAFLD Period: 2014-2016 Role: Principal Investigator Type: Investigator-Initiated Study Agency: Adheron Inc Title: Cadherin-11 expression in NASH Period: 2014-2015 Role: Principal Investigator Type: Investigator-Initiated Study Agency: Gilead Inc Title: Phospho-p-38 expression in PBMCs and liver biopsies in patients with biopsy-proven

NAFLD Period: 2015-2016


Page 11 of 27

Role: Principal Investigator Type: Investigator-Initiated Study RESEARCH GRANTS AND AWARDS (Completed) Agency: American Gastroenterological Association Foundation Title: Sucampo-ASP Designated Research Scholar Award in Geriatric Gastroenterology Sex-Specific Effect of Alcohol and Obesity and Adipocytokines in Geriatric Fatty Liver

Disease in a Prospective Population-Based-Cohort: Rancho Bernardo Study Period: 2009 – 2013 Role: Principal Investigator Agency: American Gastroenterological Association Foundation Title: T Franklin Williams Scholar Period: 2009-2012 Role: Principal Investigator Additional support from Atlantic Philanthropies and the Association from Subspecialty Professors Agency: National Science Foundaiton Title: Continuous Bulk Processing in the Cloud for NAFLD Period: 2011-2013 Role: Co-Principal Investigator (Pharmaceutical trials are not listed- can be provided on request) PRIMARY PEER REVIEWED PUBLICATIONS (* indicates a publication co-authored with a mentored trainee) 1. Loomba R. Autoimmune hepatitis: a clinical challenge. Nov 2002, Resident Rept J, published by

AGA. 2. Loomba R and Liang TJ. Novel approaches to new therapies for hepatitis B virus infection.

Antivir ther 2006; 1: 1-16. 3. Lutchman G, Modi A, Pomrat K, Kleiner D, Ghany MG, Heller T, Loomba R, Park Y, Liang TJ,

Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46(2): 424-9.

4. Loomba R and Ghany MG. Diagnosis and treatment of chronic HBeAg-negative hepatiis B. Curr Hepatitis Rept 2007; 6:146-153.

5. Loomba R and Liang TJ. Treatment of chronic hepatitis B. Antivir Ther 2007; 12 Suppl 3:H33-41.

6. Loomba R, and Ghany MG. Association of BMI and diabetes and hepatocellular carcinoma. Ann Intern Med 2008; 15: 148 (2):166-7.

7. Loomba R, Hwang SJ, O’Donnell CJ, Ellison RC, Vasan RS, D’Agostino RB, Liang TJ, and Fox CS. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology 2008; 134(4):953-9.

8. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, and Csako G. Preventive lamivudine reduces the risk of chemotherapy-induced hepatitis B virus reactivation: A systematic review. Ann Intern Med 2008;148(7):519-28.

9. Loomba R, Rowley A, Wesley R, Smith K, Liang TJ, Pucino F, and Csako G. Hepatitis B immunoglobulin and lamivudine reduce hepatitis B related morbidity and mortality post-liver transplantation: Meta-analysis. Clin Gastroenterol Hepatol. 2008; 6(6):696-700.


Page 12 of 27

10. Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE and Lavine JE. Placebo in nonalcoholic steatohepatitis: Insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol. 2008; 6(11): 1243-8.

11. Loomba R, Lutchman GA, Kleiner D, Feld J, Borg B, Modi A, Premkumar A, Sumner A, Liang TJ, and Hoofnagle JH. Clinical Trial: A pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29(2): 172-182.

12. Loomba R, Kleiner DE, and Hoofnagle JH. Mechanism of action of metformin in nonalcoholic steatohepatitis. Aliment Pharmacol Thera 2009; 29 (5): 603-604.

13. Stein L and Loomba R. Drug targets for hepatitis B virus. Infect Disord Drug Targets 2009; 9(2):105-16.

14. Loomba R, Wesley B, Bain A*, Csako G, Pucino F. Role of flouroquinolones in primary prophylaxis of spontaneous bacterial peritinotis: Meta-analysis. Clin Gastroentrol Hepatol 2009; 7(4):487-93.

15. Loomba R, Sirlin CB, Schwimmer JB and Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009; 50(4):1282-93.

16. Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, Khokar F, Lutchman G, Kleiner

DE, Young N, Childs R, Barrett JA, Liang TJ, Hoofnagle JH, Heller T. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immune suppression. Clin Gastroenetrol Hepatol 2009; 7(10):1130-7.

17. Loomba R, Bettencourt R, and Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: The Rancho Bernardo Study. Aliment Pharmacol Ther. 2009; 30 (11-12):1137-49.

18. Stein LS*, Dong MH*, and Loomba R. Insulin Sensitizers in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Current Status. Adva Ther 2009; 26(10):893-907.

19. Rotman Y, Borg BB, Soza A, Feld JJ, Modi AA, Loomba R, Lutchman G, Rivera E, Doo E, Ghany MG, Heller T, Neumann AU, Liang TJ, Hoofnagle JH. Clinical trial: low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3 - efficacy, tolerability, viral kinetics and cytokine response. Aliment Pharmacol Ther. 2010;31(9):1018-27.

20. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;6;362(18):1675-85.

21. Loomba R, Rao F, Zhang L, Khandrika S, Ziegler M, Brenner DA, and O’Connor DT. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology. 2010;139(3):836-45.

22. Loomba R, Yang YI, Su J, Brenner DA, Iloeje U, and Chen CJ. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol. 2010; 8(10):891-8, 898.

23. Chalasani NP, Guo X, Loomba R, Mark GO, Haritunians T, Kwon S, Jinrui C, Kent TD, Wilson L; Cummings WO, Chen IY, and Rotter JI. Genome-wide association scan (GWAS) of patients with histologically characterized nonalcoholic fatty liver disease (NAFLD). Gastroenterology 2010; 139(5):1567-76.

24. Dong M*, Bettencourt R, Barrett-Connor EB, and Loomba R. Alanine Aminotransferase decreases with age: The Rancho Bernardo Study. PLoS One. 2010 Dec 8;5(12):e14254

25. Loomba R, McBurney R, Vanessa-Williams, Park Y, Barbara Rehermann, Alter H, Liang TJ, Hoofnagle JH and Heller T. Acute hepatitis C: Clinical presentation, laboratory findings, and treatment outcomes. Aliment Pharmacol Ther. 2011; 33(5):559-65.

26. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011; 53(3):810-20.

27. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305(16):1659-68.


Page 13 of 27

28. Wassel CL, Loomba R, Ix JH, Allison MA, Denenberg JO, Criqui MH. Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease the San Diego population study. J Am Coll Cardiol. 2011; 58(13):1386-92.

29. Dong M*, Bettencourt R, Brenner DA, Barrett-Connor EB, and Loomba R. Serum Levels of Alanine Aminotransferase Decrease with Age in Longitudinal Analysis. Clin Gastroenterol Hepatol. 2012; 10(3):285-290.

30. Boettcher E*, Csako G, Pucino F, Wesley R, and Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2012; 35(1):66-75.

31. Lee JK*, Bettencourt R, Brenner DA, Le TA*, Barrett-Connor E , and Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: The Rancho Bernardo Study. PLoS One. 2012;7(4):e34218.

32. Le TA*, Chen J, Changchien C, Peterson M, Kono Y, Patton H, Cohen BL*, Brenner DA, Sirlin C and Loomba R for the San Diego NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial. Hepatology. 2012 Sep;56(3):922-932

33. Loomba R, Yang YI, Iloeje U, Jun Su, Brenner DA, Barrett-Connor E and Chen CJ. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013 Feb 15;177(4):333-42

34. Loomba R, Abraham MB, Unalp A, Wilson L, Lavine JE, Doo E, Bass M, and the NASH Clinical Research Network. Association between diabetes, family history of diabetes and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012 Sep; 56 (3):943-951.

35. Loomba R. Who should undergo a liver biopsy in NAFLD? AGA Perspectives 2012. Vol 8. No.3: 20-21

36. Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55(3):769-80.

37. Permutt Z*, Le TA*, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012 Jul;36(1):22-9

38. Le TA*, Loomba R. Management of nonalcoholic fatty liver disease and steatohepatitis. J Clin Exp Hepatology. 2012 Jun; 2(2): 156-73.

39. Noureddin M*, and Loomba R. Indications for liver biopsy & Non-invasive biomarkers in nonalcoholic fatty liver disease. Clinical Liver Disease. September 2012: 1, 4, 103–106

40. Abecassis M, Bridges ND, Clancy CJ, Dew MA, Eldadah B, Englesbe MJ, Flessner MF, Frank JC, Friedewald J, Gill J, Gries C, Halter JB, Hartmann EL, Hazzard WR, Horne FM, Hosenpud J, Jacobson JP, Kasiske BL, Lake J, Loomba R, Malani PN, T.M. Moore TM, Murray A, Nguyen M-H, Powe NR, Reese PP, Reynolds H, Samaniego MD, Schmader KE, Segev DL, Shah AS, Singer

LG, Sosa JA, Stewart ZA, Tan JC, Williams WW, Zaas DW, High KP. Solid Organ Transplantation in Older Adults: Current Status and Future Research. Am J Transplant. 2012 Oct;12(10):2608-22

41. Rose SC, Kikolski SG, Gish RG, Kono Y, Loomba R, Hemming AW, Wallace MJ; On behalf of the Society of Interventional Radiology. Society of interventional radiology critique and commentary on the cochrane report on transarterial (chemo) embolization. Hepatology. 2013 Apr;57(4):1675-6

42. Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012 Nov;20(11):2999-3008

43. Zarrinpar A* and Loomba R. Systematic Review: The Emerging Interplay Between Bile Acids, Gastrointestinal Tract, and Incretins in the Pathogenesis of Diabetes and Nonalcoholic Fatty Liver Disease. Aliment Pharmacol Ther. 2012 Nov;36(10):909-21

44. Loomba R, Doycheva I*, Bettencourt R, Cohen B*, Wassel C, Brenner DA, and Barrett-Connor E. Serum gamm-glutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults. J Clin Exp Hepatol. 2013 Mar 1;3(1):4-11


Page 14 of 27

45. Doycheva I*, Patel N*, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications. 2013 May-Jun;27(3):293-300

46. Patel N*, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2013 Mar;37(6):630-9.

47. Patel NS*, Loomba R. Commentary: non-alcoholic fatty pancreas -- toward an uncharted territory; authors' reply. Aliment Pharmacol Ther. 2013 May;37(9):916-7

48. Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis. Radiology. 2013 May;267(2):422-431

49. Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, Seki E. Transforming Growth Factor-β Signaling in Hepatocytes Promotes Hepatic Fibrosis and Carcinogenesis in Mice with Hepatocyte-Specific Deletion of TAK1. Gastroenterology. 2013 May; 144(5):1042-1054.

50. Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; the Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013 Jul;38(2):134-43.

51. Jensky NE, Allison MA, Loomba R, Carnethon MR, de Boer IH, Budoff MJ, Burke GL, Criqui MH, Ix JH. Null association between abdominal muscle and calcified atherosclerosis in community-living persons without clinical cardiovascular disease: The multi-ethnic study of atherosclerosis. Metabolism. 2013 Nov;62(11):1562-9

52. Loomba R and Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90

53. Patel NS*, Peterson MR, Lin GY, Feldstein A, Schnabl A, Bettencourt R, Seki E, Sirlin CB, and Loomba R. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterol Res Pract. 2013;2013:498296

54. Noureddin M*, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, and Loomba R for the NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013.Nov; 58 (5):1644-54

55. Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ. Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2013 Dec;11(12):1636-1645.

56. Noureddin M*, Lam J, Peterson M, Middleton M, Hamilton G, Le TA, Changchien C, David A. Brenner DA, Sirlin C, and Loomba R. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013 Dec;58(6):1930-40.

57. Doycheva I* and Loomba R. Effect of metformin on ballooning degeneration in NASH: When to use metformin in NAFLD. Adv Ther. 2014 Jan;31(1):30-43

58. Johnson BL, Schroeder ME, Wolfson T, Gamst AC, Hamilton G, Shiehmorteza M, Loomba R, Schwimmer JB, Reeder S, Middleton MS, Sirlin CB. Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2*-corrected, spectrum-modeled MRI. J Magn Reson Imaging. 2014 Feb; 39(2):440-7

59. Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, Seki E. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014 Feb;59(2):483-95

60. Stinton L* and Loomba R. Recommendations for liver biopsy evaluation in nonalcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2014 Mar;60(1):5-13

61. Levin YS, Yokoo T, Wolfson T, Gamst AC, Collins J, Achmad EA, Hamilton G, Middleton MS, Loomba R, Sirlin CB. Effect of echo-sampling strategy on the accuracy of out-of-phase and in-


Page 15 of 27

phase multiecho gradient-Echo MRI hepatic fat fraction estimation. J Magn Reson Imaging. 2014 Mar;39(3):567-75

62. Boland BS*, Dong MH*, Bettencourt R, Barrett-Connor E, and Loomba R. Association of serum bilirubin with aging and mortality. J Clin Exp Hepatol. 2014;4:1–7

63. Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol. 2014 Apr;10(4):219-27.

64. Negrete LM, Middleton MS, Clark L, Wolfson T, Gamst AC, Lam J, Changchien C, Deyoung-Dominguez IM, Hamilton G, Loomba R, Schwimmer J, Sirlin CB. Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J Magn Reson Imaging. 2014 May;39(5):1265-71

65. Pearlman M* and Loomba R. State of the art: Treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014 May;30(3):223-37

66. Bonekamp S, Tang A, Mashhood A, Wolfson T, Changchien C, Middleton MS, Clark L, Gamst A, Loomba R, Sirlin CB. Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2014 Jun;39(6):1525-32

67. Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander‐Tetri BA, Brunt EM, Bass NM for the NASH CRN. Coffee Consumption in NAFLD Patients with Lower Insulin Resistance is Associated with Lower Risk of Severe Fibrosis. Liver Int. 2014 Sep;34(8):1250-8

68. Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. Dig Dis Sci. 2014 Dec;59(12):3073-7.

69. Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults with Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol.2014 Dec;12(12):2121-2130.

70. Loomba R, Wolfson T, Ang B, Booker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology 2014 Dec;60(6):1920-8.

71. Tang A, Chen J, Le TA*, Changchien C, Hamilton G, Middleton MS, Loomba R, Sirlin CB. Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. Abdom Imaging. 2015 Jan;40(1):26-37.

72. Singh S*, Allen AM*, Wang Z, Prokop LJ, Murad MH, and Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-654.

73. Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, and Loomba R. Effect of Weight Loss on MRI Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology. 2015 Mar; 13(3): 561-568.

74. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of Saturated Long-chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice. Gastroenterology. 2015 Jan; 148(1):203-214.

75. Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR Imaging-estimated Proton Density Fat Fraction for Classification of Dichotomized Histologic Steatosis Grades in Nonalcoholic Fatty Liver Disease. Radiology. 2015 Feb;274(2):416-25

76. Murphy P, Hooker J, Ang B, Wolfson T, Gamst A, Bydder M, Middleton M, Peterson M, Behling C, Loomba R, Sirlin C. Associations between histologic features of nonalcoholic fatty liver disease (NAFLD) and quantitative diffusion-weighted MRI measurements in adults. J Magn Reson Imaging. 2015 Jun; 41(6): 1629-38.


Page 16 of 27

77. Loomba R, Quehenberger O, Amado A, Dennis EA. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. Journal of Lipid Research 2015 Jan; 56(1):185-92.

78. Vodkin I*, Bettencourt R, Valasek MV, Cachay E, Loomba R. Clinical, biochemical and histologic differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015 Feb;41(4):368-78

79. Lin SC*, Heba E, Wolfson T, Ang B, Gamst A, Han A, Erdman Jr. JW, O’Brien Jr. WD, Andre MP, Sirlin CB, and Loomba R. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat by new quantitative ultrasound. Clinical Gastroenterology and Hepatology 2015 Jul; 13(7): 1337-1345.

80. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. Farsenoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956-65.

81. Loomba R, Sirlin C, Ang B, Bettencourt R, Jain R*, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M*, Haufe W, Hooker C, Yin M, Ehman R, Lin G, Valasek M, Brenner D, Richards L. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel MRI and MRE in a randomized trial (MOZART Trial). Hepatology. 2015 Apr;61(4):1239-50.

82. Zarrinpar A, Gupta S, Maurya MR, Subramaniam S, Loomba R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut 2015 May 22. pii. Gutjnl-2015-309456.

83. Arulanandan A*, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients with Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2015 Aug; 13(8): 1513-20.

84. Cui J*, Ang B, Haufe W, Hernandez C, Verna EC, Sirlin CB, Loomba R. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther. 2015 Jun; 41(12):1271-80.

85. Arulanandan A. Loomba R. Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Current Hepatology Reports. 2015(14); 109-18.

86. Bazick J*, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015 Jul; 38(7):1347-55.

87. Wanner A, Groft SC, Teagarden JR, Krischer J, Davis BR, Coffey CS, Hickam, Teckman J, Nelson DR, McCaleb M, Loomba R, Strange C, Sandhaus RA, Brantly M, Edelman JM, Farrugia A. Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. Journal of COPD Foundation. 2015; 2(2): 177-190.

88. Roh YS, Zhang B, Loomba R, Seki E. TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 1; 309(1):G30-41.

89. Verna EC, Patel J, Bettencourt R, Nguyen P, Hernandez C, Valasek MA, Kisselva T, Brenner DA, Loomba R. Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2015 Sep;42(5):582-90.

90. Halldorson J, Kazi Z, Mekeel K, Kuo A, Hassanein T, Loomba R, Austin S, Valasek MA, Kishnani P, Hemming AW. Successful combined liver/kidney transplantation from a donor with Pompe disease. Mol Genet Metab. 2015 Aug; 115(4):141-4.

91. Spengler E*, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy and Treatment of NAFLD and NASH. Mayo Clinic Proceedings. 2015 Sep; 90(9): 1233-46.

92. Hamilton G, Middleton MS, Hooker JC, Haufe WM, Forbang NI, Allison MA, Loomba R, Sirlin CB. In vivo breath-hold 1 H MRS simultaneous estimation of liver proton density fat fraction,


Page 17 of 27

and T1 and T2 of water and fat, with a multi-TR, multi-TE sequence. J Magn Reson Imaging. 2015 Dec; 42(6): 1538-43.

93. Singh S*, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, Thursz MR, Loomba R, Shah VH. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. Gastroenterology. 2015 Oct; 149(4): 958-70.

94. Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh P, Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015 Oct 15; 121(20): 3631-8.

95. Singh S*, Khera R, Wang Z, Prokop LJ, Murad MH, and Loomba R. Comparative Effectiveness of Pharmacological Interventions for Non-alcoholic Steatohepatitis: A Systematic Review and Network Meta-analysis. Hepatology. 2015 Nov 12; 10(6): 552-60.

96. Singh S*, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Euro Radiology. 2016 May; 26(5): 1431-40.

97. Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, Nguyen P, Hernandez C, Richards L, Salotti J, Lin S*, Seki E, Nelson KE, Sirlin CB, Brenner D; Genetics of NAFLD in Twins Consortium. Gastroenterology. 2015 Dec; 149(7): 1784-93.

98. Mencin AA, Loomba R, Lavine JE. Caring for the children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterology and Hepatology. 2015 Nov; 12(11): 617-28.

99. Tyagi A, Yeganeh O, Levin Y, Hooker JC, Hamilton GC, Wolfson T, Gamst A, Zand AK, Heba E, Loomba R, Schwimmer J, Middleton MS, Sirlin CB. Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults. Abdominal Imaging 2015 Oct; 40(8): 3070-7.

100. Doycheva I*, Cui J*, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016 Jan 43(1): 83-95.

101. Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K and Harrison SA. Practice patterns in NAFLD and NASH: Real life differs from published guidelines. Therapeutic Advances in Gastroenterology 2016 Jan; 9(1): 4-12.

102. Cui J*, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, Valasek MA, Aryafar H, Sirlin CB, Loomba R. MRE is superior to ARFI for the diagnosis of fibrosis in patients with biopsy-proven NAFLD: A prospective study. Hepatology. 2016 Feb: 63(2): 453-61.

103. Jacobs K, Brouha S, Bettencourt R, Barrett-Connor E, Sirlin CB and Loomba R. Nonalcoholic Fatty Liver Disease, Visceral Adiposity and Coronary Artery Calcification in the Elderly. Clinical Gastroenterology and Hepatology 2016 Jan 25. pii: S1542-3565(16) 00053-7.

104. Anand G*, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016 Feb; 36(1):37-47.

105. Lin SC, Ang B, Hernandez C, Bettencourt R, Jain R, Salotti J, Richards L, Kono Y, Bhatt A, Aryafar H, Lin GY, Valasek MA, Sirlin CB, Brouha S, and Loomba R. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. Therap Adv. Gastroenterology. 2016 Mar 9: 152-61.

106. Ray Kim W, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, Aguilar Schall RE, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J, Buti M, Marcellin P. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. Journal of Hepatology 2016 Apr; 64(4): 773-80.

107. Unger JM, Hershman DL, Arnold KB, Loomba R, Chugh R, Hwang JB, O’Rourke MA, Bhadkamkar NA, Wang LX, Siegel AB, Cooley TP, Berenberg JL, Bridges BB, and Ramsey SD. Stepwise Development of A Cancer Care Delivery Research Study to Evaluate The Prevalence of Virus Infections in Cancer Patients. Future Oncol. 2016 March 8. [Epub ahead of print]


Page 18 of 27

108. Loomba R, Cui J, Wolfson T, Haufe W, Hooker J, Szeverenyi N, Ang B, Bhatt, Wang K, Aryafar H, Behling C, Valasek MA, Lin GY, Gamst A, Brenner DA, Yin M, Glaser KJ, Ehman RL, and Sirlin CB. Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective study. Am J Gastronterol. 2016 Mar 22. [Epub ahead of print]

109. Noureddin M, Anstee QM, Loomba R. Review: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016 Apr 8. [Epub ahead of print]

Editorials 1. Stinton L*, Loomba R. Dissecting the PNPLA3 association with liver fat and stiffness, and

interaction with diet. Aliment Pharmacol Ther. 2014 Apr;39(8):894-5 2. Loomba R. Serum alanine aminotransferase as a biomarker of treatment response in

nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1731-2 3. Loomba R. Rationale for conducting randomized trial to examine the efficacy of metformin in

improving survival in cirrhosis: Pleiotropic effects hypothesis. Hepatology 2014 Dec;60(6):1818-22

4. Roh YS, Loomba R, Seki E. The TM6SF2 Variants, Novel Genetic Predictors for Nonalcoholic Steatohepatitis. Gastroenterology 2015 Jan;148(1):252-4

5. Spengler EKJ*, Loomba R. Gut microbiome, Intestinal permeability, bacterial translocation and NAFLD. In press Cellular and Molecular Gastroenterology and Hepatology 2015

6. Verna EC, Loomba R. Call to screen for NAFLD and NASH in psoriasis. Aliment Pharmacol Ther. 2015 Mar;41(5):492-3

7. Loomba R, Cortez-Pinto H. Exercise and improvement of NAFLD: Practical recommendations. J Hepatol. 2015 Jul;63(1):10-2.

8. Konerman M, Loomba R. Diabetes and its association with hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2015 Jul;42(1):117-8

9. Loomba R, Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. Gastroenterology. 2015 Aug;149(2):278-81

10. Singh S and Loomba R. Obesity in chronic liver diseases - increased infections. Aliment Pharmacol Ther. 2016 Jan;43(2):311-2


Page 19 of 27

ORAL AND ABSTRACT PRESENTATIONS 1. Loomba R and Marshall JP, St. Luke’s Hospital, St. Louis. Mesocaval shunt graft migration

through the bowel wall and passing through the ileostomy. Poster presentation at ACG meeting at Seattle, Oct. 2002.

2. Loomba R, Brunt EM, Luxon BA, Bacon BR, and Neushwander-Tetri BA. Long-term outcome

of patients with autoimmune hepatitis with high or low dose prednisone as initial therapy is equal. Oral presentation in DDW, May 2002. Gastroenterology (abstr) 2002; 122:A-628: 109

3. Feld J, Gladwin M, Kleiner D, Loomba R, Liang TJ, Hoofnagle JH and Heller T. Liver Diseases

Branch, NIDDK NIH. Liver disease in sickle cell anemia. Poster presentation at AASLD, 2005. 4. Borg B, Neumann A, Ghany M, Heller T, Kleiner D, Loomba R, Liang TJ and Hoofnagle JH.

Liver Diseases Branch, NIDDK, NIH. Trial of low dose peginterferon alfa-2a and ribavirin for patients with chronic hepatitis C infected with genotype 2 or 3. Poster presentation at AASLD, 2005.

5. Lutchman G, Neumann A, Ghany M, Heller T, Loomba R, Liang TJ and Hoofnagle JH. Liver

Diseases Branch, NIDDK, NIH. Early viral kinetics in patients with chronic hepatitis C and end stage renal disease during therapy with Peginterferon -2a. Poster presentation at AASLD, 2005.

6. Ghany M, Lutchman G, Kleiner D, Borg B, Heller T, Loomba R, Liang TJ, and Hoofnagle JH.

Liver Diseases Branch, NIDDK, NIH. Lamivudine and Adefovir versus Adefovir alone for HbeAg-positive chronic hepatitis B. Poster presentation at AASLD, 2005.

7. Loomba R and Heller T. Liver Diseases Branch, NIDDK, NIH. Prospective study of liver

involvement in Turner Syndrome: elevation in liver enzymes and their relation with syndrome specific features. Poster presentation at NIDDK Fellows Retreat, 2005.

8. Loomba R, Lutchman G, Kleiner D, Heller T, Ghany M, Liang TJ and Hoofnagle JH. Liver

Diseases Branch, NIDDK, NIH. Histologic changes in nonalcoholic steatohepatitis in untreated patients: a paired liver biopsy study. Poster presentation in NASH clinical research forum in DDW, 2005.

9. Loomba R, McBurney R, Lutchman GA, Rehermann B, Herrine SK, Alter H, Liang TJ,

Hoofnagle JH and Heller T. Liver Diseases Branch, NIDDK, NIH. Acute hepatitis C: clinical presentation, laboratory findings, and treatment outcomes. Oral presentation at AASLD, 2005.

10. Loomba R, Lutchman GA, Kleiner D, Feld J, Borg B, Ghany M, Heller T, Doo E, Modi A,

Liang TJ, and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Metformin for the treatment of nonalcoholic steatohepatitis. Oral presentation at AASLD 2006.

11. Feld JJ, Lutchman GA, Loomba R, Ghany M, Heller T, Liang TJ, Neumann A, Hoofnagle JH.

Liver Diseases Branch, NIDDK, NIH, Bethesda, MD. Should peginterferon be dosed twice weekly? Poster presentation at AASLD meetings 2007.

12. Rotman Y, Borg B, Soza A, Loomba R, Modi AA, Feld JJ, Rivera E, Doo E, Heller T, Ghany

MG, Liang TJ, Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH, Bethesda, MD. Low dose peginterferon alfa-2a and ribavirin for chronic hepatitis C, genotype 2 & 3: viral kinetics, efficacy and safety. Poster presentation at AASL meetings 2007.

13. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, and Csako G. Liver

Diseases Branch, NIDDK, NIH, Bethesda, MD. Pre-emptive lamivudine reduces the risk of


Page 20 of 27

chemotherapy-induced HBV-related morbidity and mortality in HBsAg positive cancer patients: A Meta-analysis. Poster presentation at AASLD meetings 2007.

14. Loomba R, Rowley A, Wesley R, Smith K, Liang TJ, Pucino F, and Csako G. Hepatitis B

immunoglobulin and lamivudine reduce hepatitis B related morbidity and mortality post-liver transplantation: Meta-analysis. Poster presentation at DDW meetings 2008.

15. Loomba R, Bettencourt R, and Barrett-Connor E. Sex-specific association between alcohol

intake, body size and serum aminotransferase levels: The Rancho Bernardo Study. Poster presentation at AASLD meetings 2008.

16. Loomba R, Bettencourt R, Brenner D and Barrett-Connor E. Serum γ-glutamyl transpeptidase

independently predicts mortality in older adults: The Rancho Bernardo Study. Poster presentation at DDW meetings 2009.

17. Loomba R, Yang YI, Su J, Brenner DA, Iloeje U, and Chen CJ. Synergistic effect of obesity and

alcohol on risk of hepatocellular carcinoma in men: a prospective cohort study. Poster presentation at AASLD meetings 2009.

18. Loomba R, Rao F, Zhang L, Khandrika S, Ziegler M, Brenner DA, and O’Connor DT. Genetic

covariance between gamma-glutamyl transpeptidase (GGT) and fatty liver risk factors, as well as the novel effect of 2-adrenergic receptor (ADRB2) genetic variation: A twin study. Poster presentation at AASLD meetings 2009.

19. Loomba R, Yang YI, Su J, Brenner DA, Barrett-Connor E, and Chen CJ. Synergistic effect of

obesity and alcohol on risk of hepatocellular carcinoma: a prospective cohort study. Poster presentation at DDW meetings 2010.

20. Dong M, Bettencourt R, Barrett-Connor E, and Loomba R. Alanine aminotransferase decreases

with age: The Rancho Bernardo Study. Oral presentation at DDW 2010. 21. Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Chalasani NC, Kowdley K, McCullough AJ,

Diehl AM, Bass NM, Lavine JE, Brunt EM, Kleiner D, Donithan M, Van Natta M, Tonascia J, Unalp A, Clark JM, and Robuck PR for the NASH CRN. Changes in ALT and vitamin E levels and histological response in patients with NASH treated with vitamin E in the PIVENS trial. Poster presentation at AASLD 2010.

22. Boland B, Bettencourt R, Brenner DA, Barrett-connor E, and Loomba R. Association between

serum bilirubin and mortality in older adults: The Rancho Bernardo Study. Poster presentation at DDW 2011.

23. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. and the NASH

Clinical Research Network. Association between family history of diabetes and risk of nonalcoholic steatohepatitis. Poster presentation at DDW 2011.

24. Noureddin M, Vaughn I, Neuschwander-Tetri BA, Sanyal AJ, McCullough AJ, Merriman R,

Yates K, Tonascia J, Ünalp-Arida A, Doo E, Kleiner DE, Behling C, and Loomba R and the NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in the elderly. Poster presentation at AASLD 2011.

25. Le TA, Chen J, Changchien C, Peterson M, Kono Y, Patton H, Cohen BL, Brenner DA, Sirlin C

and Loomba R for the San Diego NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial”. Poster presentation at DDW 2012.


Page 21 of 27

26. Permutt Z, Le TA, Peterson M, Seki E, Brenner DA, Sirlin C and Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with nonalcoholic fatty liver disease. Poster presentation at DDW 2012.

27. Tang A, Chen J, Le TA, Changchien C, Hamilton G, Middleton MS, Sirlin CB, and Loomba R. Novel assessment of total liver fat index and liver volume using magnetic resonance imaging in patients with nonalcoholic fatty liver disease. Poster presentation at AASLD 2012.

28. Bambha K, Wilson L, Unalp A, Loomba R, Neuschwander-Tetri B, Brunt EM, and Bass NM. Coffee Consumption in NAFLD Patients with Lower Insulin Resistance is Associated with Lower Risk of Severe Fibrosis. Poster presentation at AASLD 2012.

29. Loomba R, Liu J, Yang HI, Brenner D, and Chen CJ. Synergistic interaction between family history of hepatocellular carcinoma and hepatitis B virus infection in increasing the risk of incident hepatocellular carcinoma. Poster presentation at AASLD 2012.

30. Noureddin M, Le TA, Peterson MR, Middleton MS, Hamilton G, Changchien C, Brenner D, Sirlin CB, and Loomba R. Liver fat quantification using novel magnetic resonance imaging (MRI) technique correlates robustly with MR spectroscopy and histology: A longitudinal study with repeat measures in patients with nonalcoholic fatty liver disease. Poster presentation at AASLD 2012.

31. Liu S, Bettencourt R, Schlang AM, Fehmi SAM, Brenner D, Sirlin CB, Barrett-Connor E, and Loomba R. Novel effect of aging shows decline in fatty liver despite increase in visceral fat: A prospective population-based cohort study. Poster presentation at AASLD 2012.

32. Kohli R, Dodd CN, Loomba R, Fenchel M, Belt PH, Yeh MM, Rosenthal P, Sanyal AJ, and Xanthakos S. High Serum Alpha-1-Antitrypsin Levels are Associated with More Fibrosis in NASH. Poster presentation at AASLD 2012.

33. Lavine JE, Yates KP, Brunt EM, Kleiner DE, Schwimmer JB, Murray KF, Molleston JP, Abrams SH, Rosenthal P, Loomba R, Unalp A, and Tonascia J. The natural history of nonalcoholic fatty liver disease in children and adolescents assessed in placebo recipients in the TONIC trial. Poster presentation at AASLD 2012.

34. Tang A, Szeverenyi NM, Cunha GM, Lam J, Loomba R, Ehman RL, MD Sirlin C. Liver MR Elastography: A Primer for Radiologists. Education Exhibits (Abstract ID 12022950). RSNA Chicago November 2012. Awarded Magna Cum Laude Award.

35. Loomba R, Lam J, Wolfson T, Ang B, Bhatt A, Peterson MR, Brenner DA, and Sirlin C. Magnetic Resonance Elastography Accurately Predicts Advanced Fibrosis in NAFLD: A Pilot Study with Paired-Liver Biopsy. Poster presentation at DDW 2013.

36. Vuppalanchi R, Deppe RB, Yates KP, Comerford M, Masuoka HC, Tetri BA, Loomba R, Brunt E, Kleiner DE, Tonascia J, and Chalasani NP. Changes in Serum Cytokeratin 18 Levels Significantly Predict Changes in Liver Histology in Adults With Nonalcoholic Steatohepatitis: Results from the Pivens Trial. Poster presentation at DDW 2013.

37. Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen YD, Goodarzi MO, Taylor KD, Yates KP, Unalp A, and Rotter JI. Novel Genetic Loci Associated With Steatohepatitis and Fibrosis in Hispanic Boys With Nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2013.


Page 22 of 27

38. Doycheva I, Noureddin M, Patel NS, Peterson MR, Brenner DA, Sirlin C, and Loomba R. Effect of Weight Loss on Novel MRI Quantitative Changes in Liver and Pancreatic Fat in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2013.

39. Desai A, Tang A, Wolfson T, Peterson M, Clark L, Loomba R, Middleton M, Sirlin C. Accuracy of magnetic resonance imaging (MRI) estimated proton density fat fraction (PDFF) thresholds for diagnosis of histology determined steatosis grades in adults with non-alcoholic fatty liver disease. ARRS Washington DC 2013.

40. Joshi K, Ang B, Gish R, Loomba R, Kuo A, Patton H, Kono Y, and UCSD Medicine. Hepatocellular Carcinoma Surveillance: An Inquiry Into Current Practices. Poster presentation at ILCA 2013.

41. Samala N, May KP, Kleiner DE, and Loomba R. Normal Weight Nonalcoholic Steatohepatitis (NASH). Poster presentation at AASLD 2013.

42. Loomba R, Alturki A, Han A, Lam J, Ang B, Bhatt A, Hooker J, Shah A, Zand K, Middleton MS, Wolfson T, O'Brien WD, Sirlin CB, and Andre MP. Novel quantification of liver fat by ultrasound backscatter technique & its correlation with MRI-estimated proton density fat fraction in NAFLD vs healthy controls. Poster presentation at AASLD 2013.

43. Patel N, Peterson MR, Lin GY, Bettencourt R, Sirlin CB, and Loomba R. MRI-estimated pancreatic fat is associated with insulin resistance and is greater in patients with non-alcoholic fatty liver disease than healthy controls. Poster presentation at AASLD 2013.

44. Heba E, Desai A, Wolfson T, Chavez T, Lam JC, Hooker J, Clark LG, Loomba R, Gamst A, Sirlin CB, Middleton MS. Correlation Between MRI- and MRS-estimated Proton Density Fat Fraction (PDFF) in 506 Adult Subjects with Non-alcoholic Fatty Liver Disease (NAFLD). (RSNA Abstract ID # 13020771) Poster presentation at RSNA, Chicago, 2013.

45. Alturki AT, Han A, Lam J, Hooker JC, Shah A, Zand KA, Middleton MS, O’Brien WD, Loomba R, Sirlin CB. Correlation of Quantitative Ultrasound Backscatter with 3T MRI-estimated Proton Density Fat Fraction (PDFF) for Assessment of Hepatic Steatosis. (RSNA Abstract ID # 13020530) Scientific Formal Paper presentation at RSNA, Chicago, 2013.

46. Loomba R, Wolfsen T, Haufe W, Hooker J, Szeverneyi N, Ang B, Peterson M, Valasak M, Lin G, Gamst A, Brenner DA, Sirlin CB. Novel 3-dimensional magnetic resonance elastography accurately diagnoses nonalcoholic steatohepatitis and advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective cohort study. Oral presentation at EASL, London, 2014.

47. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon S, Janssen H, Lampertico P, Lau D, Bornstein J, Schall RA, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J and Marcellin P. APRI and FIB-4 vs histology in chronic hepatitis B patients in tenofovir disoproxil fumarate trials. Poster presentation at EASL, London, 2014

48. Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine

JE, and Loomba R for the NASH CRN. Clinical model for predicting NASH or advanced fibrosis in patients with diabetes and NAFLD. Poster presentation at DDW, Chicago, 2014.

49. Singh S, Allen AA, Wang Z, Prokop LJ, Murad MH and Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver Versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies. Poster presentation at DDW, Chicago, 2014.


Page 23 of 27

50. Chang M, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine

JE, and Loomba R for the NASH CRN. Patterns in liver histology among normoglycemic, prediabetic, and diabetic patients with NAFLD. Poster presentation at DDW, Chicago, 2014.

51. Loomba R, Sirlin C, Ang B, Bettencourt R, Jain R,Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin G, Valasek M, Brenner D, Richards L. Novel MRI and MRE in ezetimibe versus placebo for the treatment of nonalcoholic steatohepatitis: Randomized-controlled trial (MOZART Trial). Poster presentation at AASLD 2014.

52. Afdhal N, Urban T, Goodman Z, Patel K, Ge D, Guo X, Jiang Z, Zhao X, Paulson M, Gaggar A, Bornstein J, Subramanian M, McHutchison J, Kleinstein S, Long N, Goldstein D, Loomba R, Thompson A. Genome Wide Association Study (GWAS) identifies a SNP near the MRC2 (mannose receptor C, type 2) gene associated with increased liver collagen content in Caucasian HBC patients. Poster presentation at AASLD 2014.

53. Ray Kim W, Loomba R, Lal P, Schall R, Johnson A, Bornstein J, Subramanian M, McHutchison J, Harrison S, Sanyal A. Serum Lysyl Oxidase Like 2 (sLOXL2) Levels Correlate with Ishak Fibrosis Score and Decrease with Treatment with Tenofovir Disoproxil Fumarate (TDF) in Patients with Chronic Hepatitis B (CHB). Poster presentation at AASLD 2014.

54. Loomba R, Wolfson T, Haufe W, Hooker J, Szeverenyi N, Ang B, Bhatt A, Behling C, Brenner D, Yin M, Ehman R, Sirlin C. Comparison of 2-dimensional and 3-dimensional magnetic resonance elastography (MRE) for diagnosis of advanced fibrosis in patients with biopsy-proven NAFLD: A prospective study. Poster presentation at AASLD 2014.

55. Lominadze Z, Harrison S, Charlton M, Loomba R, Neuschwander-Tetri B, Caldwell S, Kowdley K, Rinella M. Survey of Diagnostic and Treatment Patterns of NAFLD and NASH in the United States: Real Life Practices Differ from Published Guidelines. Poster presentation at AASLD 2014.

56. Vodkin I, Valasek M, Bettencourt R, Cachay E, Loomba R. Clinical and Histologic Differences Between HIV-associated NAFLD and Primary NAFLD: A Case-control Study. Poster presentation at AASLD 2014.

57. Lin S, Heba E, Wolfson T, Ang B, Gamst A, Han Aiguo, Erdman J, O'Brien W, Andre M, Sirlin C, Loomba R. Diagnosis and Quantification of Fatty Liver with Quantitative Ultrasound using MRI-Derived Proton Density Fat Fraction as Reference in Patients with and without NAFLD. Poster presentation at AASLD 2014.

58. Jacobs K, Brouha S, Bettencourt R, Sirlin C, Loomba R. Visceral Adiposity but not Hepatic Steatosis is Associated with Coronary Artery Calcification: a Prospective Cohort Study. Poster presentation at AASLD 2014.

59. Desai A, Bettencourt R, Loomba R. Variation in Liver Disease Related Mortality in the United States. Poster presentation at AASLD 2014.

60. Loomba R, Schork N, Chen C, Bettencourt R, Bhatt A, Ang B, Nguyen P, Hernandez H, Richards L, Salotti J, Lin S, Seki E, Nelson K, Sirlin C, and Brenner D for Genetics of NAFLD in twins consortium. Heritability of Hepatic Fibrosis and Steatosis: a Prospective Twin Study. Poster presentation at DDW 2015.

61. Loomba R and Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. Poster presentation at DDW 2015.


Page 24 of 27

62. Singh S, Khera R, Allen A, Bongiorno C, Murad M, Chandar A, Singal A, Atkinson S, Thursz, shahand Loomba R. Comparative Effectiveness of Pharmacologic treatments for Non-Alcoholic Steatohepatitis: A systematic Review and Network Meta-Analysis. Poster Presentation at DDW 2015.

63. Lin S, Ang B, Hernandez C, Bettencourt R, Jain R, Salotti J, Richards L, Kono Y, Bhatt A, Linn G, Valasek M, Sirlin C, Brouha S and Loomba R. Novel Cardiovascular Risk Assessment in the Treatment of Nonalcoholic Steatohepatitis: Secondary Analysis of the MOZART randomized Clinical Trial. Poster presentation at DDW 2015.

64. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin G, Valasek M, Ix J, Schnabl B, Sirlin C, and Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients with Non Alcoholic Fatty liver Disease Independent of Nonalcoholic Steatohepatitis. Poster presentation at DDW 2015.

65. Cui J, Wolfson T, Ang B, Haufe W, Hernandez C, Verna E, Sirlin C, and Loomba R. Magnetic Resonance Elastography Is Superior to Clinical Prediction Models for Determination of Advanced Fibrosis in Patients with Non- Alcoholic Fatty Liver Disease: A Prospective Study. Poster presentation at DDW 2015.

66. Loomba R, Schork N, Chen C, Bhatt A, Ang B, Nguyen P, Hernandez C, Richards R, Salotti J, Lin S, Nelson K, Sirlin C and Brenner D. Heritability of Hepatic Fibrosis and Hepatic Steatosis, and Their Shared Gene Effects With Metabolic Traits in NAFLD: A Prospective Twin Study. Poster presentation at DDW 2015.

67. Doycheva I, Nguyen P, Cui J, Hofflich H, Bettencourt R, Sirlin C, and Loomba R. Non- Invasive Screening for NAFLD and Advanced Fibrosis in Diabetics in Primary Care Setting by MRI and MRE: A Prospective Pilot Study. Poster presentation at DDW 2015.

68. Verna E, Patel J, Bettencourt R, Kisseleva T, Brenner D, Nguyen P, Hernandez C, and Loomba R. Novel Association Between Serum Pentraxin-2 Levels and Advanced Fibrosis in Well-Characterized Patients With NAFLD. Poster presentation at DDW 2015.

69. Zarrinpar A, Gupta S, Maurya M, Subramaniam S, and Loomba R. MicroRNAs explain the Discordance of Nonalcoholic Fatty Liver Disease in Monozygotic and Dizygotic Twins: A Prospective Human Twin Study. Poster presentation at DDW 2015.

70. Kim W.R, Berg T, Asselah T, Flisiak R, Fung S, Gordon S, Janssen H, Lampertico P, Lau D, Boornstein J, Schall R, Dinh P, Yee L, Martins E, Lim S, Loomba R, Petersen J, Buti M and Marcellin P. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic in chronic hepatitis B patients. Poster presentation at EASL 2015.

71. Loomba R, and Cortez-Pinto H. Exercise and improvement on NAFLD: Practical recommendation. Editorial at EASL 2015.

72. Cui J, Wolfson T, Ang B, Haufe W, Hernandez C, Verna E, Sirlin C, and Loomba R. Magnetic resonance Elastography is superior to clinical prediction models for determination of advanced fibrosis in patients with Non- Alcoholic Fatty Liver Disease: A Prospective Study. Oral Presentation at EASL 2015.

73. Hameed B, Terrault N, Gill R, Loomba R, Chalasani N, Hoofnagle J, and Van Natta M for the NASH CRN. Separate and combined effects of Obeticholic Acid and Weight Loss in Nonalcoholic Steatohepatitis (NASH). Poster presentation at EASL 2015.


Page 25 of 27

74. Loomba R, Schork N, Chen C-H, Bhatt A, Ang B, Nguyen P, Hernandez C, Richards L, Salotti J, Lin S, Nelson K, Sirlin C, Brenner D, on behalf of The Genetics of NAFLD in Twin Consortium. Heritability of Hepatic Fibrosis and Hepatic Steatosis and Their Shared Gene Effects with Metabolic Traits in NAFLD: A Prospective Twin Study. Oral presentation at EASL 2015.

75. Kim W, Loomba R, Berg T, Schall R, Lee Y, Dinh P, Flaherty J, Martins E, Jacobson I, Fung S, Gurel S, Buti M, and Marcellin P. HCC Risk Scores: Application of the CU-HCC, GAG-HCC and Page B scores to Chronic Hepatitis B (CHB) Patients Treated with Tenofovir Disproxil Fumerate (TDF). Poster presentation at EASL 2015.

76. Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H,

Haufe W, Hooker C, Richards L, Sirlin C, and Loomba R. Non-invasive quantitative decline in liver fat content on MRI and histological respone in nonalcoholic steatohepatitis: A secondary analysis of MOZART trial. Poster Presentation at AASLD 2015.

77. Emson C, Decaris M, Turner S, Beysen C, Li K, Hernandez C, Cui J, Lazaro L, Brenner D, Hellerstein M, and Loomba R. Novel assessment of hepatic collagen turnover rate and its quantitative association with NASH and stage of fibrosis: prospective validation of a non-invasive marker against liver biopsy. Poster presentation at AASLD 2015.

78. Goodman Z, Alaparthi L, Monge F, Patel K, Loomba R, Cadwell S, Lawitz E, Harrison S, Shiffman M, Abdelmalek M, Myers R, Schall R, Subramanian M, McHutchison J, Ratziu V, Sanyal A, and Afdhal N. Correlations between hepatic morphometric collagen contest, histologic fibrosis staging, and serum markers in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Poster presentation at AASLD 2015.

79. Loomba R, Cui J, Betttencourt, Schork N, Chen C, Ikhwan M, Bhatt A, Richards L, Sirlin C, and Brenner D. Risk of cirrhosis in first degree relatives of patients with NAFLD cirrhosis: A prospective study. Poster presentation at AASLD 2015.

80. Harrison S, Goodman Z, Ratziu V, Loomba R, Diehl A, Lawitz E, Hinrichsen H, Bambha K, Abdelmalek M, Myers R, Schall R, Subramanian M, McHutchison J, Afdhal N, and Muir A. Serum lysyl oxidase-like-2 (sLOXL2) levels correlate with fibrosis stage in patients with nonalcoholic steatohepatitis (NASH). Poster presentation at AASLD 2015.

81. Etzion O, Heller T, Han A, Patel R, Koh C, Kleiner D, Mousa O, Loomba R, Bakalov V, and Bondy C. Liver involvement in Turner Syndrome, Is Associated with Extra Hepatic Disease Manifestations. Poster presentation at AASLD 2015.

82. Huntzicker E, Goodman Z, Loomba R, Charlton M, Newstrom D, Yen E, Schall R, Subramanian M, McHutchison J, Karnik S, Myers R, and French D. Hepatic expression of the apoptosis signal-regulating kinase 1 (ASK1) marker, phosphorylated-P38 (p-P38), correlates with fibrosis stage in patients with NAFLD. Poster presentation at AASLD 2015.

83. Middleton M, Heba E, Hooker C, Neuschwander-Tetri B, Bashir M, Fowler K, Sandrasegaran K, Brunt E, Kleiner D, Doo E, Van Natta M, Tonascia J, Loomba R, and Sirlin C. Cross-sectional and longitudinal agreement of magnetic resonance imaging proton density fat fraction with pathologist grading of hepatic steatosis in adults with nonalcoholic steatohepatitis in a multi-center trial. Poster presentation at AASLD 2015.

84. Abdelmalek M, Kowdley K, Terrault N, Neuschwander-Tetri B, Sanyal S, Loomba R, Yan X, Shringarpure R, Shapiro D, and McCullough A. Effect of Biopsy length on histological response assessment in NASH trials: A secondary analysis of FLINT trial. Poster presentation at AASLD 2015.


Page 26 of 27

85. Loomba R, Sanyal A, Kowdley K, Terrault N, Chalasani N, Abdelmalek M, McCullough A, Yan X, Shringarpure R, Ferguson B, Shapiro D, and Neschwander-Tetri B. Predictors of improvement in NAFLD Activity Score to obeticholic acid: A secondary analysis of FLINT Trial. Poster presentation at AASLD 2015.

86. Lin S, Heba E, Bettencourt R, Sirlin C, and Loomba R. Cross-sectional and longitudinal analysis of advanced MRI-derived measure of liver fat and volume in the treatment of nonalcoholic steatohepatitis: A secondary analysis of RCT. Poster presentation at AASLD 2015.

87. Vuppalanchi R, Siddiqui M, Hallinan E, Abdelmalek M, Neuschwander-Tetri B, Loomba R, Kowdley K, Terrault N, McCullough A, Tonascia J, Brunt E, Kleiner D, Doo E, Chalasani N, and Sanyal A. Transient Elastography is feasible with High Success Rate for Evaluation of Non-Alcoholic Fatty Liver Disease (NAFLD) in Multicenter Setting. Poster presentation at AASLD 2015.

88. Ratziu V, Sanyal A, Loomba R, Cadwell S, Ghalib R, Torres D, McCullough A, Muir A, Myers R, Schall A, Subramanian M. McHutchison J, Bosch J, Harrison S, Abdelmalek M. Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Poster presentation at AASLD 2015.

89. Cui J, Heba E, Hernandez C, Haufe W, Hooker J, Sirlin C, and Loomba R. Magnetic Resonance Elastography is Superior to Acoustic Radiation Force Impulse for the Diagnosis of Fibrosis in Patients with Biopsy-Proven NAFLD: A prospective study. Oral presentation at AASLD 2015.

90. Hameed B, Terrault N, Gill R, Loomba R, Chalasani N, Hoofnagle J, and Van Natta M. Clinical and Metabolic Effects Associated With Weight Loss and Obeticholic Acid In Nonalcocholic Steatohepatitis (NASH). Oral presentation at AASLD 2015.

91. Chalasani N, Loomba R, Terrault N, McCullough A, Abdelmalek M, Kowdley K, Neuschwander-Tetri B, Hazra S, Yan X, Shringarpure R, MacConell L, and Sanyal A. Longitudinal changes in FIB-4 and improvement in fibrosis stage with Obeticholic acid: A secondary analysis of FLINT Trial. Oral presentation at AASLD 2015.

92. Jacobs K, Brouha S, Bettencourt R, Barrett-Connor E, Sirlin C, and Loomba R. Association of Nonalcoholic Fatty Liver Disease with Visceral Adiposity but not Coronary Artery Calcification in the Elderly. Poster Presentation at DDW 2016.

93. Loomba R. 2435163. Comparative Efficacy and Tolerability of Long-Term Pharmacological Interventions for Obesity: A Systematic Review and Network Meta-Analysis. Research Forum at DDW 2016.

94. Loomba R. 2437459. Shared Genetic Effects Between Hepatic Steatosis and Fibrosis: A Prospective Twin Study. Topic Forum at DDW 2016.

95. Loomba R. 2436771. Sitagliptin versus Placebo in the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Topic Forum at DDW 2016.

96. Loomba R. 2432689. Effect of weight loss on MRE Estimated Stiffness in Patients with Nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2016.

97. Loomba R. 2439775. Serum microRNA Profiling Differentiates NASH and Advanced Fibrosis in Well Characterized Patients with Biopsy-Proven NAFLD. Poster presentation at DDW 2016.


Page 27 of 27

98. Loomba R. 2441091. Evaluation of Effects of Concomitant Medications for NASH and Associated Comorbidities on Histological Improvements with Obeticholic Acid. Poster presentation at DDW 2016.

99. Loomba R. 2434467. Magnetic Resonance Elastography Identifies Fibrosis in Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Pilot Prospective Study. Poster Presentation a DDW 2016.

100. Loomba R, Sanyal A.J, Kowdley K.V, Terrault N, Chalasani N.P, Abdelmalek M.F, McCullough A.J, Ferguson B, Lee L, Shringarpure R, Shapiro D, and Neuschwander-Tetri B.A. Predictors of Improvement in NAFLD Activity Score on Placebo: A Secondary Analysis of the FLINT Trial. Oral presentation at EASL 2016.

101. Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hookeer J, Haufe W, Hooker C, Brenner D.A, Sirlin C.B, and Loomba R. Sitagliptin Verses Placebo in the Treatment of Non- Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Oral presentation at EASL 2016.

102. Shea P.R, Sanyal A, Rockey D.C, Loomba R, Diehl A.M, Kleinstein S.E, Myers R.P, Mani Subramanian G, McHutchison J.G, Abdelmalek M.F, Ratzui V, Afdhal N, Harrison S, Bosch J, and Goldstein D.B. Genome- Wide Association Study of Clinically Significant Portal Hypertension in Patients With Alcoholic Steatohepatitis and Advanced Fibrosis. Poster presentation at EASL 2016.

103. Cui J, Chen C-H, Lo M-T, Schork N, Bettencourt R, Bhatt A, Hooker J, Nelson K.E, Long M.T, Brenner D.A, Sirlin C.B, and Loomba R. Shared Gene Effects Between Hepatic Steatosis and Fibrosis: A Prospective Twin Study. Poster presentation at EASL 2016.

104. Kowdley K.V, Abdelmalek M.F, McCullough A.J, Loomba R, Hameed B, Shringarpure R, Shapiro D, and Sanyal A.J. Evaluation of Effects of concomitant Medications for Non- Alcoholic Steatohepatitis and Associated Comorbidities on Histological Improvements with Obeticholic Acid. Poster presentation at EASL 2016.

105. Shea P.R, Sanyal A, Harrisoon S, Ratziu V, Loomba R, Caldwell S, Diehl A.M, Kleinstein S.E, Myers R.P, Mani Subramanian G, McHutchison J.G, Abdelmalek M.F, Bosch J, Afdhal N, and Goldstein D.B. PNPLA# Variants Confer an Increased Risk of Advanced Fibrosis Due to Non- Alcoholic Steatohepatitis. Poster presentation at EASL 2016.

Documents

CURRICULUM VITAE ROHIT LOOMBA, MD, MHScjacobsschool.ucsd.edu/uploads/agile_faculty/cv/loomba_rohit.pdf · 2014 Asia Pacific Association for the Study of Liver Diseases Annual Meeting,